SCIENTIFIC CORRESPONDENCE

Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration

N T Ranson, R P Danis, T A Ciulla and L Pratt

Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202, USA

Correspondence to:
Correspondence to:
Dr Danis;
rdanis{at}iupui.edu

Background: Laser treatment of extrafoveal well delineated choroidal neovascularisation in exudative age related macular degeneration has a high rate of failure with subsequent severe vision loss from subfoveal involvement. Laser treatment may limit scotoma size, but is unpalatable because of early persistent vision loss. Intravitreal triamacinolone injection may be an acceptable alternative therapy in such disparate cases.

Methods: 14 consecutive patients with recurrent neovascularisation were treated with a single 4.0 mg injection of triamacinolone and followed for up to 1 year. Visual results were compared with published data from the Macular Photocoagulation Study of recurrent neovascularisation.

Results: Mean visual acuity remained stable at about 20/200 throughout the study period in the treated patients. This is comparable to the outcomes in the Macular Photocoagulation Study for laser retreated patients, and better than the observation group.

Conclusions: Intravitreal triamcinolone may be an acceptable treatment of subfoveal recurrent neovascularisation while avoiding early persistent vision loss from laser retreatment.

Keywords: macular degeneration; neovascularisation; laser photocoagulation; triamcinolone

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Piermarocchi, S., Sartore, M., Lo Giudice, G., Maritan, V., Midena, E., Segato, T. (2008). Combination of Photodynamic Therapy and Intraocular Triamcinolone for Exudative Age-Related Macular Degeneration and Long-Term Chorioretinal Macular Atrophy. Arch Ophthalmol 126: 1367-1374 [Abstract] [Full Text]  
• Iwama, D, Otani, A, Sasahara, M, Yodoi, Y, Gotoh, N, Tamura, H, Tsujikawa, A, Yoshimura, N (2008). Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone. Br. J. Ophthalmol. 92: 1352-1356 [Abstract] [Full Text]  
• Kosobucki, B R, Freeman, W R, Cheng, L (2006). Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br. J. Ophthalmol. 90: 705-708 [Abstract] [Full Text]  
• Zarbin, M. (2006). Should corticosteroids be considered as part of the standard care with photodynamic therapy?. Arch Ophthalmol 124: 563-571 [Full Text]  
• Jonas, J. B., Martus, P., Degenring, R. F., Kreissig, I., Akkoyun, I. (2005). Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema. Arch Ophthalmol 123: 1338-1343 [Abstract] [Full Text]  
• Spandau, U H M, Sauder, G, Schubert, U, Hammes, H-P, Jonas, J B (2005). Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br. J. Ophthalmol. 89: 745-747 [Abstract] [Full Text]  
• Bucher, R. S., Hall, E., Reed, D. M., Richards, J. E., Johnson, M. W., Zacks, D. N. (2005). Effect of Intravitreal Triamcinolone Acetonide on Susceptibility to Experimental Bacterial Endophthalmitis and Subsequent Response to Treatment. Arch Ophthalmol 123: 649-653 [Abstract] [Full Text]  
• Matsuda, S., Gomi, F., Oshima, Y., Tohyama, M., Tano, Y. (2005). Vascular Endothelial Growth Factor Reduced and Connective Tissue Growth Factor Induced by Triamcinolone in ARPE19 Cells under Oxidative Stress. IOVS 46: 1062-1068 [Abstract] [Full Text]  
• Jonas, J B, Akkoyun, I, Kreissig, I, Degenring, R F (2005). Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br. J. Ophthalmol. 89: 321-326 [Abstract] [Full Text]  
• Jonas, J B, Kreissig, I, Degenring, R F (2004). Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br. J. Ophthalmol. 88: 1557-1562 [Abstract] [Full Text]  
• Zarbin, M. A. (2004). Current Concepts in the Pathogenesis of Age-Related Macular Degeneration. Arch Ophthalmol 122: 598-614 [Abstract] [Full Text]  
• Rechtman, E, Danis, R P, Pratt, L M, Harris, A (2004). Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br. J. Ophthalmol. 88: 344-347 [Abstract] [Full Text]  
• Jonas, J. B., Akkoyun, I., Budde, W. M., Kreissig, I., Degenring, R. F. (2004). Intravitreal Reinjection of Triamcinolone for Exudative Age-Related Macular Degeneration. Arch Ophthalmol 122: 218-222 [Abstract] [Full Text]  
• Bhatt, U (2004). Are we overlooking the side effects of the drugs in our zeal to conquer ARMD?. Br. J. Ophthalmol. 88: 312-313 [Full Text]  
• Roth, D. B., Chieh, J., Spirn, M. J., Green, S. N., Yarian, D. L., Chaudhry, N. A. (2003). Noninfectious Endophthalmitis Associated With Intravitreal Triamcinolone Injection. Arch Ophthalmol 121: 1279-1282 [Abstract] [Full Text]  
• Jonas, J B, Kreissig, I, Hugger, P, Sauder, G, Panda-Jonas, S, Degenring, R (2003). Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br. J. Ophthalmol. 87: 462-468 [Abstract] [Full Text]  
• Jonas, J B, Kreissig, I, Degenring, R (2003). Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 87: 24-27 [Abstract] [Full Text]  
• Penfold, P L (2002). Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br. J. Ophthalmol. 86: 600-601 [Full Text]